Business Context and Reporting Period
Company: Skye Bioscience, Inc. (SKYE)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: Skye is a clinical-stage biopharmaceutical company developing next-generation molecules to treat obesity and metabolic diseases. The company has no revenue and is focused on advancing its lead candidate, nimacimab, for obesity. In June 2024, the company terminated its ocular program (SBI-100) following a failed Phase 2a trial and redirected resources to its metabolic program.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2024) | Value |
|---|---|
| Revenue | $0 (No revenue generated) |
| Net Loss | $(12,922,347) |
| Operating Loss | $(14,557,821) |
| Research & Development Expenses | $6,025,201 |
| General & Administrative Expenses | $8,532,620 |
| Cash and Cash Equivalents (End of Period) | $74,120,854 |
| Restricted Cash | $9,080,202 |
| Total Current Assets | $87,004,463 |
| Total Current Liabilities | $14,322,573 |
| Working Capital | $72,681,890 |
| Convertible Note (Related Party) | $4,859,525 (Carrying Value) |
| Legal Contingency Liability | $6,053,468 (Principal) + $384,896 (Accrued Interest) |
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $1.26 million (Dec 31, 2023) to $74.12 million (June 30, 2024). This was driven by two PIPE financings in January and March 2024, raising net proceeds of approximately $83.6 million.
- Expense Growth: Operating expenses increased significantly year-over-year. R&D expenses rose 103% to $6.0 million, and G&A expenses rose 173% to $8.5 million. Increases were driven by stock-based compensation, clinical trial preparation for nimacimab, and costs associated with the failed SBI-100 trial wind-down.
- Asset Disposition: The company recorded a gain of $1.15 million from the sale of the AVI building (real estate) during the six months ended June 30, 2024.
- Program Termination: The company eliminated its ocular program (SBI-100) after the Phase 2a trial failed to meet primary endpoints, incurring contract cancellation fees of approximately $270,000.
Guidance, Outlook, and Risks
- Clinical Outlook: The company expects to begin screening for the Phase 2 CBeyond trial for nimacimab in Q3 2024. Interim data is expected in Q2 2025, with topline data in Q4 2025. The trial includes an exploratory combination arm with a GLP-1 agonist.
- Capital Resources: Management believes current cash reserves are sufficient to fund operations for at least 12 months. The company entered an At-The-Market (ATM) agreement in May 2024 to sell up to $100 million of common stock, though no shares have been sold under this agreement as of the filing date.
- Legal Contingency: A significant risk remains regarding the Wendy Cunning vs. Skye Bioscience, Inc. lawsuit. The company has accrued a liability of approximately $6.44 million (including interest) based on a jury verdict. The company is appealing the verdict and pursuing insurance coverage from Partner Re Ireland Insurance DAC, but there is no guarantee of success.
- Debt Settlement: Subsequent to June 30, 2024, the $5 million convertible note held by a related party was converted into 968,973 shares of common stock.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $74 million cash balance to confirm the 12-month liquidity assertion.
- Legal Outcome: Monitor the status of the Cunning appeal and the insurance coverage dispute with Partner Re, as a loss of insurance coverage could materially impact liquidity.
- Clinical Milestones: Track the initiation of the CBeyond Phase 2 trial in Q3 2024 and the delivery of interim/topline data in 2025.
- Stock-Based Compensation: Review the impact of market-based RSU vesting on future G&A expenses, as $11.8 million in unrecognized compensation cost remains.
- ATM Utilization: Monitor if and when the company utilizes the $100 million ATM facility, which could lead to significant dilution.